SREBF2 and viral infectious disease: Considering the elevated levels of SREBP2-inhibitory 25-HC previously shown in response to viral infections (Reboldi et al., 2014), an increased cholesterol biosynthetic flux in the hyper-inflammatory phase of viral infections appears rather surprising.